Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Cardiotonic Agents Market Size Changed, over the years?
The market for cardiotonic agents has seen a quick expansion in recent times. Its size is predicted to increase from $2.78 billion in 2024 to $3.14 billion in 2025, at a compound annual growth rate (CAGR) of 12.9%. The significant growth during the historic period can be owed to various factors such as a higher frequency of heart failure, an aged population that is increasing, a greater incidence of coronary artery disease, a rise in sedentary lifestyles adoption, and increased pressure of hypertension and diabetes.
How Much Will the Cardiotonic Agents Market Be Worth in 2029?
The market for cardiotonic agents is predicted to witness accelerated expansion in the approaching years, with a projection to reach $5.06 billion by 2029, boasting a compound annual growth rate (CAGR) of 12.6%. This remarkable surge in the predicted period can be credited to the escalation in cardiovascular death rates, increasing clinical tests focused on enhancing cardiotonic formulations, growth of public-private collaborations in the development of cardiovascular drugs, an influx in hospital admissions due to heart-related issues, and a rising demand for personalized cardiovascular treatment. Key trends in the projected period comprise the development of peptide-based cardiotonic agents, evolution of dual-mechanism drugs, the inclusion of pharmacogenomics, advancements in injectable depot formulations, and the innovation of combination therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp
Which is the Largest Company in the Cardiotonic Agents Market?
Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.
What Are the Main Market Drivers in the Cardiotonic Agents Industry?
The cardiotonic agents market is expected to expand due to the escalating prevalence of cardiovascular diseases. These diseases encompass disorders impacting the heart and blood vessels, with coronary artery disease, heart failure, arrhythmias, and stroke among them. The unhealthy eating habits, replete with saturated fats, trans fats, salt, and extra sugars, lead to conditions such as obesity, high blood pressure, and high cholesterol levels, thereby causing a surge in cardiovascular diseases. Cardiotonic agents enhance the heart muscle’s efficiency and contraction strength, leading to better blood circulation and diminished symptoms of various cardiovascular diseases. In December 2023, as per the Australian Institute of Health and Welfare, a governmental agency in Australia, there was a rise in doctor-certified deaths due to coronary heart disease (CHD) from 14,100 in 2021 to 14,900 in 2022. Hence, the increasing prevalence of cardiovascular diseases is fueling the cardiotonic agents market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp
How Is the Cardiotonic Agents Market Segments Structured?
The cardiotonic agents market covered in this report is segmented –
1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Dosage Form: Tablet, Solution, Other Dosage Forms
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol
What Strategic Trends Are Transforming the Cardiotonic Agents Market?
Prominent entities in the cardiotonic agents market are concentrating on the creation of novel products such as short-term inotropic medications to ameliorate cardiovascular performance in severe heart failure and cardiogenic shock scenarios. These drugs are utilized to momentarily augment the contraction ability of the heart, leading to improved cardiac output. As an illustration, in June 2023, Hikma Pharmaceuticals plc, a pharmaceutical firm based in the UK, introduced Dobutamine Injection, USP, packaged in a 250 mg/20 mL vial. This injection is employed for short-term inotropic support in adults undergoing cardiac decompensation resulting from diminished heart contractility, usually a consequence of heart disease or post-cardiac surgery. The mode of action involves stimulating beta-1 receptors to boost muscle contractility of the heart and cardiac output swiftly (within 1–2 minutes). The injection is given intravenously and typically administered in a hospital environment under close observation.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report
Which Global Regions Offer the Highest Growth in the Cardiotonic Agents Market?
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp
This Report Delivers Insight On:
1. How big is the cardiotonic agents market, and how is it changing globally?
2. Who are the major companies in the cardiotonic agents market, and how are they performing?
3. What are the key opportunities and risks in the cardiotonic agents market right now?
4. Which products or customer segments are growing the most in the cardiotonic agents market?
5. What factors are helping or slowing down the growth of the cardiotonic agents market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model